Compare SNDX & AGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SNDX | AGM |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.7B |
| IPO Year | 2014 | N/A |
| Metric | SNDX | AGM |
|---|---|---|
| Price | $22.05 | $161.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 1 |
| Target Price | $80.69 | ★ $215.00 |
| AVG Volume (30 Days) | ★ 1.1M | 103.9K |
| Earning Date | 05-25-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.95% |
| EPS Growth | ★ 11.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $172,352,000.00 | N/A |
| Revenue This Year | $113.52 | $22.27 |
| Revenue Next Year | $52.49 | $4.06 |
| P/E Ratio | ★ N/A | $9.95 |
| Revenue Growth | ★ 627.84 | N/A |
| 52 Week Low | $8.59 | $146.69 |
| 52 Week High | $22.73 | $210.64 |
| Indicator | SNDX | AGM |
|---|---|---|
| Relative Strength Index (RSI) | 59.12 | 44.29 |
| Support Level | $19.46 | $156.98 |
| Resistance Level | $22.33 | $168.85 |
| Average True Range (ATR) | 1.01 | 5.79 |
| MACD | 0.14 | -0.20 |
| Stochastic Oscillator | 81.84 | 48.65 |
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven segments: Farm & Ranch, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA.